Resources and Insurance

Educational Materials

We hope you'll find the materials on this page useful and informative.

Full Prescribing Information (PI), including Medication Guide

Please read the patient Medication Guide before each RITUXAN treatment.

 
 

Full Prescribing Information (PI), including Medication Guide

Download PI and Medication Guide

   
 
 

NHL and RITUXAN Information Sheet

This two-sided sheet covers what NHL is, categories of NHL, and the 4 stages of NHL. It also explains how RITUXAN may be used to treat different types of NHL.

Download NHL and RITUXAN Information Sheet

   
 
 

RITUXAN and Non-Hodgkin's Lymphoma - Spanish Language Brochure

This brochure has information about treatment with RITUXAN® (Rituximab) for patients with low-grade or follicular (indolent) or DLBCL (aggressive) NHL. (In Spanish)

Download RITUXAN and NHL Spanish Brochure

   

This information does not take the place of talking with your doctor. Discuss with your doctor any questions you have about your medical condition or your treatment.


Indications

RITUXAN® (Rituximab) is indicated for the treatment of patients with:

  • Previously untreated follicular, CD20-positive, B-cell NHL in combination with first-line chemotherapy and, in patients achieving a complete or partial response to RITUXAN in combination with chemotherapy, as single-agent maintenance therapy
  • Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL, as a single agent, after first-line CVP chemotherapy
  • Previously untreated diffuse large B-cell, CD20-positive NHL in combination with CHOP or other anthracycline-based chemotherapy regimens
  • Relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent

People with serious infections should not receive RITUXAN.

Important Safety Information

  • RITUXAN can cause serious side effects that can lead to death, including infusion reactions, tumor lysis syndrome (TLS; kidney failure due to fast breakdown of cancer cells), severe skin and mouth reactions, and progressive multifocal leukoencephalopathy (PML; a rare, serious brain infection).
  • RITUXAN has also been associated with serious and life-threatening side effects, including the return of active hepatitis B virus infection with sudden and serious liver problems including liver failure, and death, other serious infections that can lead to death, heart problems, kidney problems, and stomach and serious bowel problems including blockage and tears in the bowel that can sometimes lead to death.
  • The most common side effects of RITUXAN seen in patients with non-Hodgkin's lymphoma were infusion reactions, fever, chills, low white blood cells, infections, body aches, and tiredness. Before starting treatment with RITUXAN it is important to talk to your doctor about your medical history.
  • Tell your doctor about any side effect that bothers you or that does not go away. These are not all of the possible side effects with RITUXAN. For more information, ask your doctor.

Please see full Prescribing Information, including Medication Guide.

CVP=cyclophosphamide, vincristine, and prednisone or prednisolone; CHOP=cyclophosphamide, doxorubicin, vincristine, and prednisone.